Auteurs
Analysis
Allemagne
Racine
Analysis
Allemagne
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « Paolo Lanzetta »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Paolo Gresele < Paolo Lanzetta < Paolo Lombardi  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000E78 (2014) Ursula Schmidt-Erfurth [Autriche] ; Gabriele E. Lang [Allemagne] ; Frank G. Holz [Allemagne] ; Reinier O. Schlingemann [Pays-Bas] ; Paolo Lanzetta [Italie] ; Pascale Massin [France] ; Ortrud Gerstner [Suisse] ; Abdelkader Si Bouazza [Suisse] ; Haige Shen [République populaire de Chine] ; Aaron Osborne [Suisse] ; Paul Mitchell [Australie]Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
001972 (2011) Sebastian Wolf [Suisse] ; Frank G. Holz [Allemagne] ; Jean-François Korobelnik [France] ; Paolo Lanzetta [Italie] ; Paul Mitchell [Australie] ; Christian Prünte [Autriche] ; Ursula Schmidt-Erfurth [Autriche] ; Andreas Weichselberger [Suisse] ; Yehia Hashad [Suisse]Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR

List of associated KwdEn.i

Nombre de
documents		Descripteur
2Ranibizumab
1Acuity
1Acute bcva loss
1Age related macular degeneration
1Analysis
1Anchor patients
1Anchor study
1Anchor trials
1Angiogenesis Inhibitors (adverse effects)
1Angiogenesis Inhibitors (therapeutic use)
1Antibodies, Monoclonal, Humanized (adverse effects)
1Antibodies, Monoclonal, Humanized (therapeutic use)
1Baseline
1Baseline characteristics
1Bcva
1Bcva change
1Bcva loss
1Bcva outcomes
1Blindness
1Choroidal neovascularisation
1Classic occult
1Control patients
1Degeneration
1Diabetes Mellitus, Type 1 (complications)
1Diabetes Mellitus, Type 2 (complications)
1Diabetic Retinopathy (drug therapy)
1Diabetic Retinopathy (physiopathology)
1Evolution
1Female
1Humans
1Intraocular pressure
1Intravitreal Injections
1Laser Coagulation
1Macular
1Macular Edema (drug therapy)
1Macular Edema (physiopathology)
1Macular degeneration
1Male
1Marina trials
1Middle Aged
1Neovascular
1Neovascular macular degeneration
1Neovascularization
1Novartis
1Novartis pharma
1Ophthalmol
1Ophthalmology
1Pharma
1Photodynamic treatment
1Precision Medicine
1Prognosis
1Ranibizumab treatment
1Retina (pathology)
1Retinal pigment epithelium
1Retreatment
1Severe bcva loss
1Sham
1Sham control group
1Sham treatment
1Sickness Impact Profile
1Study baseline
1Surveys and Questionnaires
1Time Factors
1Total area
1Treatment
1Treatment Outcome
1Visual Acuity (physiology)
1Visual acuity

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Paolo Lanzetta" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "Paolo Lanzetta" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Paolo Lanzetta
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024